Advertisement

Tumor Markers in Genitourinary Cancer

  • H. Barton Grossman
  • T. Ming Chu
Part of the Cancer Treatment and Research book series (CTAR, volume 19)

Abstract

Tumor markers have become increasingly important in the management of genitourinary malignant neoplasms. For the purpose of this discussion, I will use a broad definition of tumor markers that is based on their potential clinical use. With this perspective, a tumor marker may be defined as any biochemical, hormonal, or immunologic assay which provides information regarding the diagnosis and/or prognosis of a malignant neoplasm. In addition to the obvious potential clinical importance of tumor markers, they may also prove to be useful tools for basic scientists in the study of the pathophysiology of human malignancy. Tumor markers may be highly specific for a given neoplasm or may be quite non-specific. However, their clinical relevance, which does not always correlate with specificity, will determine whether they will be incorporated into the urologic oncologist’s armamentarium or not. A number of factors will determine whether an individual tumor marker will be clinically accepted. Obvious relevant factors include the prevalence of the neoplasm; its actual or perceived impact on the population at risk; and the sensitivity and specificity of the tumor marker itself. Sensitivity refers to the accuracy of the tumor marker in detecting neoplasm when it is actually present. An insensitive test will produce false negative results, i.e., failure to detect neoplasm when it is actually present.

Keywords

Bladder Cancer Tumor Marker Acid Phosphatase Benign Prostatic Hyperplasia Human Chorionic Gonadotropin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Yam LT: Clinical significance of the human acid phosphatase. A review. Am J Med 56:604–616, 1974.PubMedGoogle Scholar
  2. 2.
    Chu TM, Wang MC, Lee CL, Killian CS, Valenzuela LA, Wajsman Z, Slack N, Murphy GP: Enzyme markers for prostate cancer. Cancer Detect and Prev 2:693–706, 1979.Google Scholar
  3. 3.
    Goldenberg SL, Silver HBK, Sullivan LD, Morse MJ, Archibald EL: A critical evaluation of specific radioimmunoassay for prostatic acid phosphatase. Cancer 50:1847–1851, 1982.PubMedGoogle Scholar
  4. 4.
    Lee CL, Chu TM, Wajsman LZ, Slack NH, Murphy GP: Value of new fluorescent immunoassay for human prostatic acid phosphatase in prostate cancer. Urology 15:338–341, 1980.PubMedGoogle Scholar
  5. 5.
    Bruce AW, Mahan DE, Sullivan LD, Goldenberg L: The significance of prostatic acid phosphatase in adenocarcinoma of the prostate. J Urol 125:357–360, 1981.PubMedGoogle Scholar
  6. 6.
    Quinones GR, Rohner TJ Jr, Drago JR, Demers LM: Will prostatic acid phosphatase determination by radioimmunoassay increase the diagnosis of early prostatic cancer? J Urol 125:361–364, 1981.PubMedGoogle Scholar
  7. 7.
    Watson RA, Tang DB: The predictive value of prostatic acid phosphatase as a screening test for prostatic cancer. N Engl J Med 303:497–499, 1980.PubMedGoogle Scholar
  8. 8.
    Pontes JE, Choe B, Rose N, Pierce JM Jr: Reliability of bone marrow acid phosphatase as a parameter of metastatic prostatic cancer. J Urol 122:178–179, 1979.PubMedGoogle Scholar
  9. 9.
    Romas NA, Veenema RJ, Hsu KC, Tomashefsky P, Lattimer JK, Tannenbaum M: Bone marrow acid phosphatase and prostatic cancer: An assessment by immunoassay and biochemical methods. J Urol 123:392–395, 1980.PubMedGoogle Scholar
  10. 10.
    Cooper JF, Foti A, Herschman H: Combined serum and bone marrow radioimmunoassay for prostatic acid phosphatase. J Urol 122:498–501, 1979.PubMedGoogle Scholar
  11. 11.
    Belville WD, Mahan DE, Sepulveda RA, Bruce AW, Miller CF: Bone marrow acid phosphatase by radioimmunoassay: Three years of experience. J Urol 125:809–811, 1981.PubMedGoogle Scholar
  12. 12.
    Vihko P, Kontturi M, Lukkarinen O, Vihko R: Radioimmunoassayable prostate-specific acid phosphatase in peripheral and bone marrow sera compared in diagnosis of prostatic cancer patients. J Urol 128:739–741, 1982.PubMedGoogle Scholar
  13. 13.
    Li CY, Lam KW, Yam LT: Immunohistochemical diagnosis of prostatic cancer with metastases. Cancer 46:706–712, 1980.PubMedGoogle Scholar
  14. 14.
    Bates RJ, Chapman CM, Prout GR Jr, Lin C-W: Immunohistochemical idenfication of prostatic acid phosphatase: correlation of tumor grade with acid phosphatase distribution. J Urol 127:574–580, 1982.PubMedGoogle Scholar
  15. 15.
    Sarosdy MF, Kledzik G, Lamm DL: Serum and bone marrow radioimmunoassay of acid phosphatase in prostatic cancer. Urology 19:33–36, 1982.PubMedGoogle Scholar
  16. 16.
    Khan AN, Lee GS, Jackett DMR, Newcombe RG, Pathy MS: The effect of routine digital examination of the prostate on serum acid phosphatase. Br J Urol 50:182–184, 1978.PubMedGoogle Scholar
  17. 17.
    Vihko P, Lukkarinen O, Contturi M, Vihko R: The effect of manipulation of the prostate gland on serum prostate-specific acid phosphatase measured by radioimmunoassay. Invest Urol 18:334–336, 1981.PubMedGoogle Scholar
  18. 18.
    Pearson JC, Dombrovskis S, Dreyer J, Williams RD: Radioimmunoassay of serum prostatic acid phosphatase after prostatic massage. Urology 21:37–41, 1983.PubMedGoogle Scholar
  19. 19.
    Johnson DE, Prout GR, Scott WW, Schmidt JD, Gibbons RP, Murphy GP: Clinical significance of serum acid phosphatase levels in advanced prostatic carcinoma. Urology 8:123–126, 1976.PubMedGoogle Scholar
  20. 20.
    Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a human prostate specific antigen. Invest Urol 17:159–163, 1979.PubMedGoogle Scholar
  21. 21.
    Papsidero LD, Kuriyama M, Wang MC, Horoscewicz J, Leon SS, Valenzuela L, Murphy GP, Chu TM: Prostate Antigen: A marker for human prostate epithelial cells. J Natl Cancer Inst 66:37–42, 1981.PubMedGoogle Scholar
  22. 22.
    Nadji M, Tabei SZ, Castro A, Chu TM, Murphy GP, Wang MC, Morales AR: Prostatic-specific antigen: An immunohistologic marker for prostatic neoplasms. Cancer 48:1229–1232, 1981.PubMedGoogle Scholar
  23. 23.
    Wang MC, Papsidero LD, Kuriyama MM, Valenzuela LA, Murphy GP, Chu TM: Prostate antigen: A new potential marker for prostatic cancer. Prostate 2:89–96, 1981.PubMedGoogle Scholar
  24. 24.
    Kuriyama M, Wang MC, Lee C, Papsidero LD, Killian CS, Inaji H, Slack NH, Nishiura T, Murphy GP, Chu TM: Use of prostate-specific antigen in monitoring prostate cancer. Cancer Res 41:3874–3876.Google Scholar
  25. 25.
    Frankel AE, Rouse RV, Wang MC, Chu TM, Herzenberg LA: Monoclonal Antibodies to human prostate antigen. Cancer Res 42:3714–3718, 1982.PubMedGoogle Scholar
  26. 26.
    Ware JL, Paulson DF, Parks SF, Webb KS: Production of monoclonal antibody αPro3 recognizing a human prostatic carcinoma antigen. Cancer Res 42:1215–1222, 1982.PubMedGoogle Scholar
  27. 27.
    Clark SM, Merchant DK, Starling JJ: Monoclonal antibodies against a soluble cytoplasmic antigen in human prostatic epithelial cells. Prostate 3:203–214, 1982.Google Scholar
  28. 28.
    Starling JJ, Sieg SM, Beckett ML, Schellhammer PF, Ladaga LE, Wright GL Jr: Monoclonal antibodies to human prostate and bladder tumor-associated antigens. Cancer Res 42:3084–3089, 1982.PubMedGoogle Scholar
  29. 29.
    Ghanadian R, Auf G, Williams G: Relationship between prostatic cytoplasmic and nuclear androgen receptors in patients with carcinoma of the prostate. Eur Urol 7:39–40, 1981.PubMedGoogle Scholar
  30. 30.
    Ekman P: Steroid receptors in urological malignancies. Acta Obstet Gynecol Scand (Suppl) 101:87–92, 1981.Google Scholar
  31. 31.
    Trachtenberg J, Walsh PC: Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J Urol 127:466–471, 1982.PubMedGoogle Scholar
  32. 32.
    Hoisaeter PA, Haukaas S, Bakke A, Hoiem L, Segadal E, Thorsen T: Blood hormone levels related to stages and grades of prostatic cancer. Prostate 3:375–381, 1982.PubMedGoogle Scholar
  33. 33.
    Rannikko S, Kairento A-L, Karonen S-L, Adlercreutz H: Hormonal pattern in prostatic cancer. I. Correlation with local extent of tumour, presence of metastases and grade of differentiation. Acta Endocrinol 98:625–633, 1981.PubMedGoogle Scholar
  34. 34.
    Mooppan MMU, Wax SH, Kim H, Wang JC, Tobin MS: Urinary hydroxyproline excretion as a marker of osseous metastasis in carcinoma of the prostate. J Urol 123:694–696, 1980.PubMedGoogle Scholar
  35. 35.
    Rinsho K, Aoyagi K: Urinary hydroxyproline excretion as a marker of bone metastasis in prostatic cancer. Tohoku J Exp Med 137:461–462, 1982.PubMedGoogle Scholar
  36. 36.
    Hopkins SC, Nissenkorn I, Palmieri GMA, Ikard M, Moinuddin M, Soloway MS: Serial sport hydroxyproline/creatinine ratios in metastatic prostatic cancer. J Urol 129:319–323, 1983.PubMedGoogle Scholar
  37. 37.
    Moss AJ Jr, Bissada NK, Boyd CM, Hunter WC: Significance of protein-bound neuraminic acid levels in patients with prostatic and bladder carcinoma. Urology 13:182–184, 1979.PubMedGoogle Scholar
  38. 38.
    Grayhack JT, Wendel EF, Oliver L, Lee C: Analysis of specific proteins in prostatic fluid for detecting prostatic malignancy. J Urol 121:295–299, 1979.PubMedGoogle Scholar
  39. 39.
    Fair WR, Heston WD, Kadmon D, Crane DB, Catalona WJ, Ladenson JH, McDonald JM, Noll BW, Harvey G: Prostatic cancer, acid phosphatase, creatinine kinase-BB and race: A prospective study. J Urol 128:735–738, 1982.PubMedGoogle Scholar
  40. 40.
    Pretlow TG II, Whitehurst GB, Pretlow TP, Hunt RS, Jacobs JM, McKenzie DR, McDaniel HG, Hall LM, Bradley EL Jr: Decrease in creatinine kinase-BB in human prostatic carcinoma compared to benign prostatic hyperplasia. Cancer Res 42:4842–4848, 1982.PubMedGoogle Scholar
  41. 41.
    Juengst D, Pickel A, Elsaesser E, Marx FJ, Karl HJ: Urinary cholesterol excretion in men with benign prostatic hyperplasia and carcinoma of the prostate. Cancer 43:353–359, 1979.PubMedGoogle Scholar
  42. 42.
    Kovarik S, Davidsohn I, Stejskal R: ABO antigens in cancer. Detection with the mixed cell agglutination reaction. Arch Pathol 86:12–21, 1968.PubMedGoogle Scholar
  43. 43.
    Decenzo JM, Howard P, Irish CE: Antigenic deletion and prognosis of patients with stage a transitional cell bladder carcinoma. J Urol 114:874–878, 1975.PubMedGoogle Scholar
  44. 44.
    Hall L, Faddoul A, Saberi A, Edson M: The use of the red cell surface antigen to predict the malignant potential of transitional cell carcinoma of the ureter and renal pelvis. J Urol 127:23–25, 1982.PubMedGoogle Scholar
  45. 45.
    Wiley EL, Mendelsohn G, Droller MJ, Eggleston JC: Immunoperoxidase detection of carcinoembryonic antigen and blood group substances in papillary transitional cell carcinoma of the bladder. J Urol 128:276–280, 1982.PubMedGoogle Scholar
  46. 46.
    Limas C, Lange P: Altered reactivity for A, B, H antigens in transitional cell carcinomas of the urinary bladder. A study of the mechanisms involved. Cancer 46:1366–1373, 1980.PubMedGoogle Scholar
  47. 47.
    Catalona WJ: Practical utility of specific red cell adherence test in bladder cancer. Urology 18:113–117, 1981.PubMedGoogle Scholar
  48. 48.
    Javadpour N: Immunocytochemical localization of various markers in cancer cells and tumors. Diagnostic and therapeutic strategy in urologic cancers. Urology 21:1–7, 1983.PubMedGoogle Scholar
  49. 49.
    Grossman HB: Hybridoma antibodies reactive with human bladder carcinoma cell surface antigens. J Urol 130:610–614, 1983.PubMedGoogle Scholar
  50. 50.
    Gozzo JJ, Cronin WJ, O’Brien P, Monaco AP: Detection of tumor-associated antigens in urine from patients with bladder cancer. J Urol 124:804–807, 1980.PubMedGoogle Scholar
  51. 51.
    Betkerur V, Baumgartner G, Talluri K, Sharifi R, Nagubadi S, Guinan P: Urinary immunoglobulin A in the diagnosis of bladder cancer. J Surg Oncol 16:215–217, 1981.PubMedGoogle Scholar
  52. 52.
    Pastorini P, Milano G, Toubol J, Raymond G, Cambon P, Lalanne CM: The diagnostic and prognostic value of urinary polyamine measurement in bladder cancer. Urol Res 9:13–16, 1981.PubMedGoogle Scholar
  53. 53.
    Jungst D, Tauber R, Osterholzer M, Karl HJ: Is urinary cholesterol determination a possible screening test for urological carcinomas? Urol Res 9:1–3, 1981.PubMedGoogle Scholar
  54. 54.
    Jungst D, Osterholzer M, Tauber R, Karl HJ: Urinary cholesterol in cancer screening. Urology 20:495–498, 1982.PubMedGoogle Scholar
  55. 55.
    Murphy WM, Vandevoorde JP, Rao MK, Solo way MS: The clinical value of urinary carcinoembryonic antigen-like substances in urothelial cancer. J Urol 118:806–808, 1977.PubMedGoogle Scholar
  56. 56.
    Glashan RW, Higgins E, Neville AM: The clinical value of plasma and urinary carcinoembryonic antigen (CEA) assays in patients with hematuria and urothelial carcinoma. Eur Urol 6:344–346, 1980.PubMedGoogle Scholar
  57. 57.
    El-Sayed LH, Hassan EM, Amin AM, Ismail AA: Immunocytochemical studies of carcinoembryonic antigen (CEA) in bilharzial bladder. Neoplasma 29:233–235, 1982.PubMedGoogle Scholar
  58. 58.
    Jautzke G, Altenaehr E: Immunohistochemical demonstration of carcinoembryonic antigen (CEA) and its correlation with grading and staging on tissue sections of urinary bladder carcinomas. Cancer 50:2052–2056, 1982.PubMedGoogle Scholar
  59. 59.
    O’Brien P, Gozzo JJ, Monaco AP: Urinary proteins as biological markers: Bladder cancer diagnosis versus urinary tract infection. J Urol 124:802–803, 1980.PubMedGoogle Scholar
  60. 60.
    Wajsman Z, Williams PD, Greco J, Murphy GP: Further study of fibrinogen degradation products and bladder cancer detection. Urology 12:659–661, 1978.PubMedGoogle Scholar
  61. 61.
    Bastable JRG, Richards B, Haworth S, Cooper EH: Acute phase reactant proteins in the clinical management of carcinoma of the bladder. Br J Urol 51:283–289, 1979.PubMedGoogle Scholar
  62. 62.
    Mandell J, Magee MC, Fried FA: Hypercalcemia associated with uroepithelial neoplasms. J Urol 119:844–845, 1978.PubMedGoogle Scholar
  63. 63.
    Kitajima K, Satoh Y, Okada K, Kishimoto T: Human chorinic gonadotropin-like substance (hCG-LS)-producing urothelial carcinoma: Immunohistological location of hCG-LS. Jpn J Clin Oncol 12:49–56, 1982.Google Scholar
  64. 64.
    Gupta NP, Malaviya AN, Singh SM: Rheumatoid factor: Correlation with recurrence in transitional cell carcinoma of the bladder. J Urol 121:417–418, 1979.PubMedGoogle Scholar
  65. 65.
    Sufrin G, Tritsch GL, Mittleman A, Murphy GP: Adenosine deaminase activity in patients with carcinoma of the bladder. J Urol 119:343–346, 1978.PubMedGoogle Scholar
  66. 66.
    Khanderia U, Keller JH, Grossman HB: Serum sialic acid is a biologic marker for malignant disease. J Surg Oncol 23:163–166, 1983.PubMedGoogle Scholar
  67. 67.
    Lamb D: Correlation of chromosome counts with histological appearances and prognosis in transitional-cell carcinoma of bladder. Br Med J 1:273–277, 1967.PubMedGoogle Scholar
  68. 68.
    Sandberg AA: Chromosome markers and progression in bladder cancer. Cancer Res 37:2950–2956, 1977.PubMedGoogle Scholar
  69. 69.
    Summers JL, Falor WH, Ward R: A 10-year analysis of chromosomes in non-invasive papillary carcinoma of the bladder. J Urol 125:177–178, 1981.PubMedGoogle Scholar
  70. 70.
    Tribukait B, Gustafson H, Esposti P: Ploidy and proliferation in human bladder tumors as measured by flow-cytofluorometric DNA analysis and its relations to histopathology and cytology. Cancer 43:1742–1751, 1979.PubMedGoogle Scholar
  71. 71.
    Gustafson H, Tribukait B, Esposti PL: DNA profile and tumour progression in patients with superficial bladder tumours. Urol Res 10:13–18, 1982.PubMedGoogle Scholar
  72. 72.
    Altaffer LF III, Chenault OW Jr: Paraneoplastic endocrinopathies associated with renal tumors. J Urol 122:573–577, 1979.PubMedGoogle Scholar
  73. 73.
    Lebel M, Talbot J, Grose J, Morin J: Adenocarcinoma of the kidney and hypertension: report of two cases with special emphasis on renin. J Urol 118:923–927, 1977.PubMedGoogle Scholar
  74. 74.
    Sufrin G, Mirand EA, Moore RH, Chu TM, Murphy GP: Hormones in renal cancer. J Urol 117:433–438, 1977.PubMedGoogle Scholar
  75. 75.
    Buckle RM, McMillan M, Mallinson C: Ectopic secretion of parathyroid hormone by a renal adenocarcinoma in a patient with hypercalcaemia. Br Med J 4:724–726, 1970.PubMedGoogle Scholar
  76. 76.
    Concolino G, Marocchi A, Conti C, Tenaglia R, Di Silverio F, Bracci U: Human renal cell carcinoma as a hormone-dependent tumor. Cancer Res 38:4340–4344, 1978.PubMedGoogle Scholar
  77. 77.
    Di Fronzo G, Ronchi E, Bertuzzi A, Vezzoni P, Pizzocaro G: Estrogen receptors in renal carcinoma. Eur Urol 6:307–311, 1980.PubMedGoogle Scholar
  78. 78.
    Chen L, Weiss FR, Chaichik S, Keydar I: Steroid receptors in human renal carcinoma. Isr J Med Sci 16:756–760, 1980.PubMedGoogle Scholar
  79. 79.
    Sufrin G, Mink I, Fitzpatrick J, Moore R, Murphy GP: Coagulation factors in renal adenocarcinoma. J Urol 119:727–730, 1978.PubMedGoogle Scholar
  80. 80.
    Vickers M Jr: Serum haptoglobins: A preoperative detector of metastatic renal carcinoma. J Urol 112:310–312, 1974.PubMedGoogle Scholar
  81. 81.
    Babaian RJ, Swanson DA: Serum Haptoglobin: A nonspecific tumor marker for renal cell carcinoma. South Med J 75:1345–1348, 1982.PubMedGoogle Scholar
  82. 82.
    Bunning RAD, Haworth SL, Cooper EH: Serum beta-2-microglobulin levels in urological cancer. J Urol 121:624–625, 1979.PubMedGoogle Scholar
  83. 83.
    Sanford EJ, Drago JR, Rohner TJ, Kessler GF, Sheehan L, Lipton A: Preliminary evaluation of urinary Polyamines in the diagnosis of genitourinary tract malignancy. J Urol 113:218–221, 1975.PubMedGoogle Scholar
  84. 84.
    Duckett JW, Koop CE: Neuroblastoma. Urol Clin North Am 4:285–295, 1977.PubMedGoogle Scholar
  85. 85.
    Gittes RF, Mahoney EM: Pheochromocytoma. Urol Clin North Am 4:239–252, 1977.PubMedGoogle Scholar
  86. 86.
    LaBrosse EH, Imashuku S, Fineberg SE: Distribution and turnover of 7–3H-methoxy-4-hydroxymandelic acid in a patient with ganglioneuroma. J Clin Endocrinol Metab 35:753–761, 1972.PubMedGoogle Scholar
  87. 87.
    Evans AE: Staging and treatment of neuroblastoma. Cancer 45:1799–1802, 1980.PubMedGoogle Scholar
  88. 88.
    Laug WE, Siegel SE. Shaw KNF, Landing B, Baptista J, Gutenstein M: Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics 62:77–83, 1978.PubMedGoogle Scholar
  89. 89.
    Juan D: Pheochromocytoma: Clinical manifestations and diagnostic tests. Urology 17:1–12, 1981.PubMedGoogle Scholar
  90. 90.
    Peterson DD, Brown DR, Woods JW, Cole AG, Fried FA: Pheochromocytoma: recent experience with detection and management. Urology 10:133–138, 1977.PubMedGoogle Scholar
  91. 91.
    Bravo EL, Tarazi RC, Gifford RW, Stewart BH: Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. N Engl J Med 301:682–686, 1979.PubMedGoogle Scholar
  92. 92.
    Jiang N-S, Stoffer SS, Pikler GM, Wadel O, Sheps SG: Laboratory and clinical observations with a two-column plasma catecholamine assay. Mayo Clin Proc 48:47–49, 1973.PubMedGoogle Scholar
  93. 93.
    Fukushima DK, Gallagher TF: Steroid production in ‘non-functioning’ adrenal cortical tumor. J Clin Endocrinol 23:923–927, 1963.Google Scholar
  94. 94.
    Richie JP, Gittes RF: Carcinoma of the adrenal cortex. Cancer 45:1957–1964, 1980.PubMedGoogle Scholar
  95. 95.
    Didolkar MS, Bescher RA, Elias EG, Moore RH: Natural history of adrenal cortical carcinoma: A clinicopathologic study of 42 patients. Cancer 47:2153–2161, 1981.PubMedGoogle Scholar
  96. 96.
    Sullivan M, Boileau M, Hodges CV: Adrenal cortical carcinoma. J Urol 120:660–665, 1978.PubMedGoogle Scholar
  97. 97.
    Drago JR, Sheikholislam B, Olstein JS, Palmer JM, Tesluk H, Link D: Virilizing adrenal cortical carcinoma with hypertrophy of spermatic tubules in childhood. Urology 14:70–75, 1979.PubMedGoogle Scholar
  98. 98.
    Javadpour N: The role of biologic tumor markers in testicular cancer. Cancer 45:1755–1761, 1980.PubMedGoogle Scholar
  99. 99.
    Javadpour N: Significance of elevated serum alpha-fetoprotein (AFP) in seminoma. Cancer 45:2166–2168, 1980.PubMedGoogle Scholar
  100. 100.
    Kurman RJ, Scardino PT, Mclntire KR, Waldmann TA, Javadpour N: Cellular localization of alpha-fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using an indirect immunoperoxidase technique. A new approach to classification utilizing tumor markers. Cancer 40:2136–2151, 1977.PubMedGoogle Scholar
  101. 101.
    Wagener C, Menzel B, Breuer H, Weissbach L, Tschubel K, Henkel K, Gedigk P: Immunohistochemical localization of alpha-fetoprotein (AFP) in germ cell tumours: evidence for AFP production by tissues different from endodermal sinus tumour. Oncology 38:236–239, 1981.PubMedGoogle Scholar
  102. 102.
    Javadpour N: Biologic tumor markers in management of testicular and bladder cancer. Urology 12:177–183, 1978.PubMedGoogle Scholar
  103. 103.
    Javadpour N, Soares T, Princier GL: In vitro synthesis of alpha-fetoprotein and human chorionic gonadotropin in testicular cancer. Cancer 49:303–307, 1982.PubMedGoogle Scholar
  104. 104.
    Javadpour N: Management of Seminoma based on tumor markers. Urol Clin North Am 7:773–780, 1980.PubMedGoogle Scholar
  105. 105.
    Bosl GJ, Lange PH, Fraley EE, Goldman A, Nochomovitz LE, Rosai J, Waldmann TA, Johnson K, Kennedy BJ: Human chorionic gonadotropin and alpha-fetoprotein in the staging of nonseminomatous testicular cancer. Cancer 47:328–332, 1981.PubMedGoogle Scholar
  106. 106.
    Barzell WE, Whitmore WF Jr: Clinical significance of biologic markers: memorial hospital experience. Semin Oncol 6:48–52, 1979.PubMedGoogle Scholar
  107. 107.
    Skinner DG, Scardino PT: Relevance of biochemical tumor markers and lymphadenectomy in management of non-seminomatous testis tumors: current perspective. J Urol 123:378–382, 1980.PubMedGoogle Scholar
  108. 108.
    Catalona WJ, Vaitukaitis JL, Fair WR: Falsely positive human chorionic gonadotropin assays in patients with testicular tumors: Conversion to negative with testosterone administration. J Urol 122:126–128, 1979.PubMedGoogle Scholar
  109. 109.
    Javadpour N, Soares T: False-positive and fase-negative alpha-fetoprotein and human chorionic gonadotropin assays in testicular cancer: A double blind study. Cancer 48:2279–2281, 1981.PubMedGoogle Scholar
  110. 110.
    Fowler JE Jr: Observations on reliability of commercial assay for alpha-fetoprotein. Urology 19:275–277, 1982.PubMedGoogle Scholar
  111. 111.
    Vugrin D, Whitmore WF Jr, Nisselbaum J, Watson RC: Correlation of serum tumor markers and lymphangiography with degrees of nodal involvement in surgical stage II testis cancer. J Urol 127:683–684, 1982.PubMedGoogle Scholar
  112. 112.
    Javadpour N, Woltering E, Soares T: Simultaneous measurement of tumor cytosol and peripheral serum levels of human chorionic gonadotropin and alphafetoprotein in testicular cancer. Invest Urol 18:11–12, 1980.PubMedGoogle Scholar
  113. 113.
    Javadpour N, Chen H-C: Improved human chorionic gonadotropin on concentrated 24-hour urine in patients with testicular cancer. J Urol 126:176–178, 1981.PubMedGoogle Scholar
  114. 114.
    Willemse PHB, Slejifer DT, Koops HS, De Bruijan H WA, Oosterhuis JW, Bruwers TM, Ockhuizen T, Marrink J: The value of AFP and HCG half lives in predicting the efficacy of combination chemotherapy in patients with non-seminomatous germ cell tumors of the testis. Oncodev Biol Med 2:129–234, 1981.PubMedGoogle Scholar
  115. 115.
    Vogelzang NJ, Lange PH, Goldman A, Vessela RH, Fraley EE, Kennedy BJ: Acute changes of a-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer res 42:4855–4861, 1982.PubMedGoogle Scholar
  116. 116.
    Lange PH, Vogelzang NJ, Goldman A, Kennedy BJ, Fraley EE: Marker half-life analysis as a prognostic tool in testicular cancer. J Urol 128:708–711, 1982.PubMedGoogle Scholar
  117. 117.
    Javadpour N: Radioimmunoassay and immunoperoxidase of pregnancy specific beta-1 glycoprotein in sera and tumor cells of patients with certain testicular germ cell tumors. J Urol 123:514–515, 1980.PubMedGoogle Scholar
  118. 118.
    Lange PH, Bremner RD, Home CHW, Vessella RL, Fraley EE: Is SP-1 a marker for testicular cancer? Urology 15:251–255, 1980.PubMedGoogle Scholar
  119. 119.
    Javadpour N, Utz M, Soares T: Immunocytochemical discordance in localization of pregnancy specific beta-1 glycoprotein, alpha-fetoprotein and human chorionic gonadotropin in testicular cancers. J Urol 124:615–616, 1980.PubMedGoogle Scholar
  120. 120.
    Szymendera JJ, Zborzil J, Sikorowa L, Kaminska JA, Gadek A: Value of five tumor markers (AFP, CEA, hCG, hPL and SP1) in diagnosis and staging of testicular germ cell tumors. Oncology 38:222–229, 1981.PubMedGoogle Scholar
  121. 121.
    Lieskovsky G, Skinner DG: Significance of serum lactic dehydrogenase in stages B and C non-seminomatous testis tumors. J Urol 123:516–517, 1980.PubMedGoogle Scholar
  122. 122.
    Johnson H Jr, Flye MW, Javadpour N: Serum β2 microglobulin levels in patients with testicular cancer. Urology 16:522–524, 1980.PubMedGoogle Scholar
  123. 123.
    Uchida T, Shimoda T, Miyata H, Shikata T, Iino S, Suzuki H, Oda T, Hirano K, Sugiura M: Immunoperoxidase study of alkaline phosphatase in testicular tumor. Cancer 48:1455–1462, 1981.PubMedGoogle Scholar
  124. 124.
    Jeppsson A, Wahren B, Stigbrand T, Edsmyr F, Andersson L: A clinical evaluation of serum placental alkaline phosphatase in seminoma patients. Br J Urol 55:73–78, 1983.PubMedGoogle Scholar
  125. 125.
    Lee M, Ray PS, Sharifi R: Elevated serum calcitonin associated with an extragonadal seminoma. J Urol 128:392–394, 1982.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1984

Authors and Affiliations

  • H. Barton Grossman
  • T. Ming Chu

There are no affiliations available

Personalised recommendations